E&Y Sees $1-5 Billion As Sweet Spot For Biotech M&A

14.06.2011 - Biotech deals in the $1 billion to $5 billion range are likely to be a sweet spot for drug companies looking to bolster their pipelines through M&A in an increasingly tough...